Correct Answer: A. Active surveillance
Active surveillance is the standard of care for low-risk prostate cancer in elderly patients. This case presents low-risk disease: PSA 9 ng/mL (borderline but not elevated), Gleason score 6 (well-differentiated, lowest risk category), and small tumor focus in a 75-year-old. According to D'Amico risk stratification, Gleason ≤6 with PSA <10 ng/mL constitutes low-risk disease. In elderly men with limited life expectancy (<10–15 years), the morbidity of radical treatment (incontinence, erectile dysfunction, bowel toxicity) outweighs survival benefit. Active surveillance involves regular PSA monitoring (every 3–6 months), digital rectal examination, and repeat biopsy if PSA velocity increases or Gleason grade upgrades. This approach defers treatment until disease progression, preserving quality of life. Indian urological practice and international guidelines (NCCN, EAU) recommend surveillance for low-risk, localized prostate cancer in elderly patients. The patient's age (75 years) with comorbidities makes him a poor candidate for aggressive intervention.
Why the other options are wrong
B. External beam radiation — External beam radiation is reserved for intermediate- to high-risk disease or when surgery is contraindicated. In low-risk, localized prostate cancer with Gleason 6, radiation causes unnecessary toxicity (rectal bleeding, urinary frequency, erectile dysfunction) without survival advantage over surveillance. This represents overtreatment in an elderly patient with limited life expectancy. C. Brachytherapy — Brachytherapy (permanent seed implantation) is indicated for intermediate-risk disease or as monotherapy in selected low-risk cases with longer life expectancy (>15 years). At age 75 with small tumor focus and Gleason 6, this patient is not an ideal candidate. Brachytherapy carries risks of urinary retention, incontinence, and rectal toxicity—inappropriate for surveillance-eligible disease. D. Radical prostatectomy — Radical prostatectomy is curative but carries significant morbidity (incontinence in 5–20%, erectile dysfunction in 50–80%) and mortality risk in elderly patients. At 75 years with low-risk disease (Gleason 6, PSA 9), the patient's life expectancy may not justify the perioperative and long-term functional risks. Surgery is reserved for younger, fit patients with intermediate- to high-risk disease.
High-Yield Facts
- D'Amico low-risk prostate cancer: Gleason ≤6 + PSA <10 ng/mL + clinical stage T1c–T2a; active surveillance is standard of care.
- Active surveillance protocol: PSA every 3–6 months, DRE annually, repeat biopsy if PSA velocity >0.75 ng/mL/year or Gleason upgrade.
- Age >70 years with Gleason 6: Life expectancy <15 years makes aggressive treatment (surgery/radiation) inappropriate; surveillance preferred.
- Gleason 6 prostate cancer: Lowest-risk histology; rarely progresses to metastatic disease; overtreatment is a major concern in elderly men.
- PSA 9 ng/mL: Borderline value; in context of Gleason 6 and small focus, does not mandate immediate intervention in elderly patients.
Mnemonics
LADS for Low-Risk Prostate Cancer Low Gleason (≤6), Age >70, Diameter small, Surveillance. When all four present, active surveillance is the answer. PSA-Gleason Rule of Thumb PSA <10 + Gleason ≤6 = Watch & Wait. PSA 10–20 or Gleason 7 = Intermediate (consider treatment). PSA >20 or Gleason ≥8 = High-risk (treat aggressively).
NBE Trap
NBE pairs "elderly patient" with "small tumor" to tempt selection of radiation or surgery, overlooking that Gleason 6 (the most critical discriminator) mandates surveillance. Students who focus on age alone without integrating Gleason score fall into this trap.
Clinical Pearl
In Indian urology practice, overtreatment of low-risk prostate cancer in elderly men is common due to patient anxiety and PSA-driven diagnosis. Active surveillance respects the natural history of Gleason 6 disease (which rarely metastasizes) and preserves continence and potency—critical quality-of-life factors in elderly Indian patients with limited life expectancy.
_Reference: Bailey & Love Ch. 48 (Prostate Cancer Management); Harrison Ch. 91 (Neoplasms of the Prostate)_